Overview

Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients

Status:
Completed
Trial end date:
2019-06-19
Target enrollment:
Participant gender:
Summary
To investigate the safety and tolerability of ascending repeated oral doses of BAY1817080 in healthy volunteers(Part1). To investigate the safety, tolerability and efficacy of BAY1817080 in patients with refractory chronic cough(Part2).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bayer